Synapse - Lindsey Roeker

Search Within

Lindsey Elizabeth Roeker

Results (143)

Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence

Meeting Abstract

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
Blood (2021)

Fulltext@MSK | Save

Outcomes of chronic lymphocytic leukemia and Richter Transformation following discontinuation of noncovalent Bruton's Tyrosine Kinase inhibitors

Meeting Abstract

Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Pagel, J. M.; Jensen, J. L.; Battiato, K. E.; Fox, Y.; Meyer, K.; Bailey, N.; Rhodes, J. M.; more...
Blood (2021)

Fulltext@MSK | Save

Addressing a new challenge in chronic lymphocytic leukemia: Outcomes of therapies after exposure to both a covalent Bruton's Tyrosine Kinase Inhibitor and venetoclax

Meeting Abstract

Thompson, M. C.; Roeker, L. E.; Coombs, C. C.; Jensen, J. L.; Kamdar, M.; Skarbnik, A.; Pagel, J. M.; Bailey, N.; Pu, J. J.; Jacobs, R.; more...
Blood (2021)

Fulltext@MSK | Save

A phase 1a/b dose escalation study of the mutation agnostic BTK/FLT3 inhibitor luxeptinib (CG-806) in patients with relapsed or refractory B-cell malignancies

Meeting Abstract

Samaniego, F.; Burke, J. M.; Mahadevan, D.; Cherry, M.; Sadiq, A. A.; Koontz, M. Z.; Villasboas, J. C.; Reid, E.; Cull, E.; Priego, V.; more...
Blood (2021)

Fulltext@MSK | Save

A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach

Meeting Abstract

Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
Blood (2021)

Fulltext@MSK | Save

Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study

Meeting Abstract

Mato, A. R.; Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Munir, T.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; more...
Blood (2021)

Fulltext@MSK | Save

Radiation therapy for patients with diffuse large B cell Richter's syndrome of CLL

Meeting Abstract

Sacchi De Camargo Correia, G.; Imber, B. S.; Hajj, C.; Thompson, M. C.; Mato, A. R.; Yahalom, J.; Roeker, L. E.
Blood (2021)

Fulltext@MSK | Save

A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (Trial in progress)

Meeting Abstract

Alencar, A. J.; Roeker, L. E.; Hoffman, M.; Murthy, G. S. G.; Patel, V.; Ku, N. C.; Pauff, J. M.; Eyre, T. A.; Jurczak, W.; Le Gouill, S.
Blood (2021)

Fulltext@MSK | Save

Disease- and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies

Journal Article

Chung, D. J.; Shah, G. L.; Devlin, S. M.; Ramanathan, L. V.; Doddi, S.; Pessin, M. S.; Hoover, E.; Marcello, L. T.; Young, J. C.; Boutemine, S. R.; more...
Blood Cancer Discovery (2021)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial

Journal Article

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
The Lancet Haematology (2021)

Fulltext@MSK | Save